Peptides and peptide mimetics to treat pathologies associated with eye disease
OwnerGattadahalli M. Anantharamaiah, Alan M. Fogelman +2inventors
InventorsGattadahalli M. Anantharamaiah, Alan M. Fogelman, Mohamad Navab, Martin Rudolf
Life of this patent
Estimating the term…
Abstract
This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.
Claims24
A method for treating a subject with eye disease, the method comprising administering to the subject in need thereof an effective amount of one or more of the active agents described in SEQ ID NOS:
- 1-1208 in an amount sufficient to ameliorate one or more symptoms of said condition.
A method of ameliorating a symptom of eye disease, the method comprising a) administering to the subject an effective amount of a peptide wherein said peptide ranges in length from about 18 to 37 amino acids and comprises at least 3 alanines (A), 2 aspartates (D), 2 glutamates (E), 4 phenylalanines (F), 4 lysines (K), 1 valine (V), 1 tryptophan (W), 1 tyrosine (Y);
- b) wherein said peptide forms a class A amphipathic helix;
- c) comprises at least one “D” amino acid residue;
- and d) protects a phospholipid against oxidation by an oxidizing agent.
A method for treating a subject with eye disease, the method comprising administering to the subject in need thereof an effective amount of one or more of the active agents described in SEQ ID NOS:
- 1-1208 in an amount sufficient to ameliorate one or more symptoms of said condition in combination with an anti-angiogenic therapy.
A method of ameliorating a symptom of eye disease, the method comprising administering to the subject in need thereof an effective amount of one or more of the active agents described in SEQ ID NOS:
- 1-1208 in an amount sufficient to ameliorate one or more symptoms of said condition in combination with an anti-angiogenic therapy.
Dependencies are inferred from the claim text.